Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SZSE:300813'
s EV-to-FCF Range Over the Past 10 Years
Min: -17.31 Med: 93.97 Max: 14156.35
Current: 101.17
During the past 10 years, the highest EV-to-FCF of Zhejiang Tailin Bioengineering Co was 14156.35. The lowest was -17.31. And the median was 93.97.
SZSE:300813's EV-to-FCF is ranked worse than 89.93% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 22.87
vs SZSE:300813: 101.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Tailin Bioengineering Co (SZSE:300813) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zhejiang Tailin Bioengineering Co's PE Ratio (TTM) for today is calculated as:
Zhejiang Tailin Bioengineering Co's share price for today is ¥19.85.
Zhejiang Tailin Bioengineering Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.194.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zhejiang Tailin Bioengineering Co EV-to-FCF Related Terms
Zhejiang Tailin Bioengineering Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SZSE:300813 vs ABT, SYK, MDT: EV-to-FCF Comparison
For the Medical Devices subindustry, Zhejiang Tailin Bioengineering Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Tailin Bioengineering Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zhejiang Tailin Bioengineering Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zhejiang Tailin Bioengineering Co's EV-to-FCF falls into.
Zhejiang Tailin Bioengineering Co's current Enterprise Value is ¥2,144.6 Mil.
Zhejiang Tailin Bioengineering Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥11.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Tailin Bioengineering Co (SZSE:300813) has a EV-to-FCF of 181.52 as of Sep. 16, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Tailin Bioengineering Co and its competitors. This is 93% above median its historical median of 93.97. According to the industry distribution chart, Zhejiang Tailin Bioengineering Co ranks #375 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 89.9%.
Is Zhejiang Tailin Bioengineering Co's EV-to-FCF too high?
Zhejiang Tailin Bioengineering Co's current EV-to-FCF of 181.52 is 93% above median its 10-year median of 93.97. The Medical Devices & Instruments industry median EV-to-FCF is 22.87. Zhejiang Tailin Bioengineering Co's value of 181.52 is 693.7% above this industry median. Based on the distribution chart, Zhejiang Tailin Bioengineering Co ranks #375 out of 417 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Zhejiang Tailin Bioengineering Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Tailin Bioengineering Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zhejiang Tailin Bioengineering Co ranks #375 out of 417 companies for EV-to-FCF. This places Zhejiang Tailin Bioengineering Co in the lower half of its industry. The industry median EV-to-FCF is 22.87. Zhejiang Tailin Bioengineering Co's value of 181.52 is 693.7% above this benchmark. While the company's 10-year median is 93.97 vs. the industry median of 22.87, Zhejiang Tailin Bioengineering Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.87, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Tailin Bioengineering Co's current EV-to-FCF of 181.52 is 693.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zhejiang Tailin Bioengineering Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Tailin Bioengineering Co's current EV-to-FCF is 181.52, which is 93% above median its own 10-year median of 93.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Tailin Bioengineering Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Tailin Bioengineering Co (SZSE:300813) is currently considered Fairly Valued. The stock's GF Value™ is ¥20.96, compared to a current price of ¥19.85 — trading 5.3% below its estimated fair value. The current EV-to-FCF is 181.52, which is 93% above median its 10-year median of 93.97 and 693.7% above the Medical Devices & Instruments industry median of 22.87. Zhejiang Tailin Bioengineering Co's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zhejiang Tailin Bioengineering Co (SZSE:300813), the current EV-to-FCF is 181.52 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Tailin Bioengineering Co (SZSE:300813) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Tailin Bioengineering Co stock appears to be undervalued.
The current stock price of ¥19.85 is trading 5.3% below its estimated GF Value™ of ¥20.96.
GuruFocus considers Zhejiang Tailin Bioengineering Co to be Fairly Valued.
Key valuation signals for SZSE:300813:
EV-to-FCF: 181.52 (93% above median its 10-year median of 93.97)
GF Value™: ¥20.96 vs. price of ¥19.85 (5.3% below fair value)
Industry Position: 693.7% above the Medical Devices & Instruments median (#375 of 417)
No single metric tells the full story. See the SZSE:300813 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SZSE:300813 has been successfully added to your 
